Atara to Suspend Development of Protein Energy Wasting Treatment

Atara Biotherapeutics is suspending further development of PINTA 745 for the treatment of protein energy wasting in patients with end-stage renal disease after the candidate fell short of its goal in a Phase 2 trial.

Atara says it will shift its focus to its portfolio of clinical stage oncology and immunotherapy product candidates.